Results from several recent clinical studies have demonstrated that TIMP-1 levels in cancer patient plasma are elevated and the elevated TIMP-1 levels are associated with worse clinical outcomes in many cancer types including prostate and colon cancer [23-34]. This evidence concerns the gene TIMP1 and cancer.